FDA Adds Study Data to Schizophrenia Drug Labeling FDA Adds Study Data to Schizophrenia Drug Labeling

The FDA has approved inclusion of ' real-world ' data from the phase 3 PRIDE trial in product labeling for the once-monthly antipsychotic paliperidone palmitate in schizophrenia.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Psychiatry News Source Type: news